How Neuropeptides Drive Severe Itching in Bullous Pemphigoid | Research

The takeaway

Substance P, neurokinin 1 receptor, and IL-31 signaling are key drivers of itch in bullous pemphigoid, offering potential therapeutic targets.

24 patients
BP patients whose skin lesions were analyzed for itch mediator expression

What the researchers found

Itch severity in bullous pemphigoid correlates with eosinophils, substance P, neurokinin 1 receptor, IL-31 signaling, IL-13, periostin, and basophils, while mast cells and TRPV1 were not significantly correlated.

Why it matters

Identifying specific neuropeptide and immune pathways driving itch in BP could lead to targeted therapies like NK1R antagonists or anti-IL-31 drugs, replacing broad immunosuppression.

The numbers in context

24 BP patients; 6 controls; itch correlated with SP, NK1R, IL-31RA, eosinophils, IL-13, periostin, basophils

How the study worked

Immunofluorescence staining of skin lesions from 24 BP patients and 6 healthy controls, with correlation analysis between mediator expression and itch severity.

Who was studied

24 bullous pemphigoid patients and 6 healthy controls

What this study cannot tell us

Small sample size (30 total). Cross-sectional design cannot establish causation. Limited to immunofluorescence analysis without functional assays.

How to read the evidence

Small observational study providing correlational evidence. Immunofluorescence-only analysis without functional validation limits conclusions.

When this study was published

Published in 2020, the findings remain relevant as targeted anti-itch therapies continue to develop.

The bigger picture

Understanding neuropeptide-driven itch mechanisms in autoimmune blistering diseases opens the door to targeted anti-itch treatments that could benefit patients with BP and related conditions.

Questions still open

Would NK1R antagonists effectively reduce itch in BP patients?
Do anti-IL-31 therapies like nemolizumab work for BP-associated itch?
Why are mast cells not correlated with itch severity despite their established role in other pruritic conditions?

Common questions

What causes the severe itching in bullous pemphigoid?

This study found that multiple neuropeptide and immune signals drive BP itch, including substance P, neurokinin 1 receptor, IL-31 signaling, and eosinophils. The itch appears to be mediated through both nervous system and immune pathways.

Are there targeted treatments for BP itch?

The findings suggest substance P blockers (NK1R antagonists) and anti-IL-31 therapies could target BP itch specifically, though clinical trials are needed to confirm this.

Read the original research

Pathophysiologic mechanisms of itch in bullous pemphigoid.

Journal of the American Academy of Dermatology, 83(1), 53-62

View on PubMed ↗Publisher’s paper ↗

Citation

Hashimoto, Takashi; Kursewicz, Christina Dorothy; Fayne, Rachel Alison; Nanda, Sonali; Shah, Serena Maya; Nattkemper, Leigh; Yokozeki, Hiroo; Yosipovitch, Gil. (2020). Pathophysiologic mechanisms of itch in bullous pemphigoid.. Journal of the American Academy of Dermatology, 83(1), 53-62. https://doi.org/10.1016/j.jaad.2019.07.060